These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34009625)

  • 1. Molecular, Solid-State and Surface Structures of the Conformational Polymorphic Forms of Ritonavir in Relation to their Physicochemical Properties.
    Wang C; Rosbottom I; Turner TD; Laing S; Maloney AGP; Sheikh AY; Docherty R; Yin Q; Roberts KJ
    Pharm Res; 2021 Jun; 38(6):971-990. PubMed ID: 34009625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ritonavir: an extraordinary example of conformational polymorphism.
    Bauer J; Spanton S; Henry R; Quick J; Dziki W; Porter W; Morris J
    Pharm Res; 2001 Jun; 18(6):859-66. PubMed ID: 11474792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Solvent Selection on the Crystallizability and Polymorphic Selectivity Associated with the Formation of the "Disappeared" Form I Polymorph of Ritonavir.
    Wang C; Ma CY; Hong RS; Turner TD; Rosbottom I; Sheikh AY; Yin Q; Roberts KJ
    Mol Pharm; 2024 Jul; 21(7):3525-3539. PubMed ID: 38900600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapsone Form V: A Late Appearing Thermodynamic Polymorph of a Pharmaceutical.
    Braun DE; Vickers M; Griesser UJ
    Mol Pharm; 2019 Jul; 16(7):3221-3236. PubMed ID: 31075201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural analysis of polymorphism and solvation in tranilast.
    Vogt FG; Cohen DE; Bowman JD; Spoors GP; Zuber GE; Trescher GA; Dell'orco PC; Katrincic LM; Debrosse CW; Curtis Haltiwanger R
    J Pharm Sci; 2005 Mar; 94(3):651-65. PubMed ID: 15666296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization.
    Morissette SL; Soukasene S; Levinson D; Cima MJ; Almarsson O
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2180-4. PubMed ID: 12604798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparities of Single-Particle Growth Rates in Buried Versus Exposed Ritonavir Crystals within Amorphous Solid Dispersions.
    Griffin SR; Takanti N; Sarkar S; Song Z; Vogt AD; Danzer GD; Simpson GJ
    Mol Pharm; 2020 Dec; 17(12):4564-4571. PubMed ID: 33151697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Habit Modification of the Active Pharmaceutical Ingredient Lovastatin Through a Predictive Solvent Selection Approach.
    Turner TD; Hatcher LE; Wilson CC; Roberts KJ
    J Pharm Sci; 2019 May; 108(5):1779-1787. PubMed ID: 30590015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface effects on the crystallization of ritonavir glass.
    Kawakami K
    J Pharm Sci; 2015 Jan; 104(1):276-9. PubMed ID: 25382848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabrication, solid state characterization and bioavailability assessment of stable binary amorphous phases of Ritonavir with Quercetin.
    Dengale SJ; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
    Eur J Pharm Biopharm; 2015 Jan; 89():329-38. PubMed ID: 25542681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ritonavir Form III: A New Polymorph After 24 Years.
    Yao X; Henry RF; Zhang GGZ
    J Pharm Sci; 2023 Jan; 112(1):237-242. PubMed ID: 36195132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational Energy Landscape of the Ritonavir Molecule.
    Chakraborty D; Sengupta N; Wales DJ
    J Phys Chem B; 2016 May; 120(19):4331-40. PubMed ID: 27123749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthon Approach in Crystal Engineering to Modulate Physicochemical Properties in Organic Salts of Chlorpropamide.
    Menon AM; Sidhartha NN; Shruti I; Suresh A; Meena R; Dikundwar AG; Chopra D
    Mol Pharm; 2024 Jun; 21(6):2894-2907. PubMed ID: 38688017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PH-induced nanosegregation of ritonavir to lyotropic liquid crystal of higher solubility than crystalline polymorphs.
    Rodríguez-Spong B; Acciacca A; Fleisher D; Rodríguez-Hornedo N
    Mol Pharm; 2008; 5(6):956-67. PubMed ID: 19434919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational flexibility and hydrogen-bonding patterns of the neotame molecule in its various solid forms.
    Dong Z; Munson EJ; Schroeder SA; Prakash I; Grant DJ
    J Pharm Sci; 2002 Sep; 91(9):2047-56. PubMed ID: 12210051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes.
    Aruksakunwong O; Wolschann P; Hannongbua S; Sompornpisut P
    J Chem Inf Model; 2006; 46(5):2085-92. PubMed ID: 16995739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding pharmaceutical polymorphic transformations II: crystallization variables and influence on dosage forms.
    Sood J; Sapra B; Bhandari S; Tiwary AK
    Ther Deliv; 2015; 6(6):721-40. PubMed ID: 26149787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extension of the dissolution-precipitation model for kinetic elucidation of solvent-mediated polymorphic transformations.
    Jakubiak P; Schuler F; Alvarez-Sánchez R
    Eur J Pharm Biopharm; 2016 Dec; 109():43-48. PubMed ID: 27648958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical Stabilization of Pharmaceutical Glasses Based on Hydrogen Bond Reorganization under Sub-T
    Tominaka S; Kawakami K; Fukushima M; Miyazaki A
    Mol Pharm; 2017 Jan; 14(1):264-273. PubMed ID: 28043129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Annealing in the Close Vicinity of
    Kamińska E; Minecka A; Tarnacka M; Hachuła B; Kamiński K; Paluch M
    Mol Pharm; 2020 Mar; 17(3):990-1000. PubMed ID: 31961694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.